Broadwood Partners, L.P. Acquires 3,240 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Company (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 3,240 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was purchased at an average price of $21.94 per share, for a total transaction of $71,085.60. Following the completion of the purchase, the insider owned 15,426,144 shares in the company, valued at approximately $338,449,599.36. The trade was a 0.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, January 7th, Broadwood Partners, L.P. bought 66,467 shares of STAAR Surgical stock. The stock was purchased at an average cost of $22.00 per share, for a total transaction of $1,462,274.00.
• On Tuesday, January 6th, Broadwood Partners, L.P. bought 336,946 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.62 per share, for a total transaction of $7,284,772.52.
• On Wednesday, November 19th, Broadwood Partners, L.P. purchased 309,132 shares of STAAR Surgical stock. The shares were purchased at an average price of $26.42 per share, with a total value of $8,167,267.44.
• On Friday, November 21st, Broadwood Partners, L.P. acquired 797,486 shares of STAAR Surgical stock. The stock was acquired at an average price of $27.86 per share, for a total transaction of $22,217,959.96.
• On Thursday, November 20th, Broadwood Partners, L.P. acquired 393,382 shares of STAAR Surgical stock. The stock was acquired at an average cost of $27.14 per share, for a total transaction of $10,676,387.48.

STAAR Surgical Trading Down 1.7%

Shares of NASDAQ STAA opened at $22.12 on Friday. STAAR Surgical Company has a 12-month low of $13.50 and a 12-month high of $30.81. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.34 and a beta of 1.00. The firm has a 50 day moving average of $25.01 and a 200 day moving average of $24.41.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday. Piper Sandler reaffirmed a “neutral” rating on shares of STAAR Surgical in a research note on Monday, October 27th. Canaccord Genuity Group boosted their price objective on STAAR Surgical from $28.00 to $30.75 and gave the company a “hold” rating in a research note on Tuesday, December 9th. BTIG Research reissued a “neutral” rating on shares of STAAR Surgical in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of STAAR Surgical in a report on Wednesday, October 8th. Ten analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, STAAR Surgical currently has an average rating of “Reduce” and an average target price of $23.42.

Institutional Trading of STAAR Surgical

Several institutional investors and hedge funds have recently added to or reduced their stakes in STAA. CWM LLC boosted its stake in STAAR Surgical by 74.1% in the 2nd quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 665 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 1,016 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of STAAR Surgical by 61.4% in the third quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 706 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of STAAR Surgical by 691.0% during the second quarter. PNC Financial Services Group Inc. now owns 3,607 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 3,151 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 4,673 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.